70 results about "Mast cell" patented technology

The invention discloses a novel application of bifidobacterium longum subsp. Infantis CCFM1269 in relieving atopic dermatitis, and belongs to the technical field of microorganisms. The bifidobacterium longum subsp. Infantis CCFM1269 provided by the invention can relieve atopic dermatitis, and is specifically reflected in that (1) ear swelling and back skin thickening of mice are relieved, dermatological symptoms are relieved, and mast cell infiltration is reduced; (2) reducing the total IgE level of serum; (3) the Treg level of mesenteric lymph nodes and the ILA content of serum are improved; (4) IL-4 and TSLP levels in skin tissues are reduced, IL-10 is improved, and Th1 / Th2 immune balance is recovered; (5) improving AHR and CYP1A1 in the skin tissue; and (4) high yield of ILA.

The invention discloses a novel application of bifidobacterium breve CCFM1078 in relieving atopic dermatitis, and belongs to the technical field of microorganisms. The bifidobacterium breve CCFM1078 provided by the invention can relieve atopic dermatitis, and is specifically reflected in that (1) ear swelling and back skin thickening of mice are relieved, dermatological symptoms are relieved, and mastocyte infiltration is reduced; (2) the relative expression quantity of mRNA (messenger Ribonucleic Acid) of mouse skin barrier function related genes is increased; (3) reducing the total IgE level of mouse serum; (4) reducing the levels of IL-4, IL-13 and TSLP in mouse skin tissues, improving the levels of IL-10 and IFN-gamma, recovering Th1 / Th2 immune balance, and maintaining immune homeostasis; (5) activating the expression of AHR and CYP1A1 in the skin tissue of the mouse; (6) improving IgA and sIgA secretion of mouse colon tissue; and (7) compared with a representative high-yield ILA strain, the ILA yield is higher.

The application discloses application of volatile oil of Citrus aurantium in preparation of a medicine for preventing and treating allergic rhinitis. The application proposes that the volatile oil of Citrus aurantium can significantly reduce the levels of mast cell factors IL-1beta and TNF-alpha, and can also significantly reduce the levels of inflammatory factors IL-13 and IL-4 in mice, reduce inflammatory cell infiltration, and reduce eosinophilic granulocyte increase and gland hyperplasia. The application proposes that the volatile oil of Citrus aurantium has great potential as a medicinal and edible raw material for treating allergic rhinitis. The application also proposes that the volatile oil of Citrus aurantium can significantly improve symptoms such as sneezing, runny nose, and nasal itching of mice caused by allergic rhinitis, and the symptoms seriously affect the life of patients.

The present invention relates to a composition for improving skin, which comprises beta-sitosterol and betulin and, in the case of the composition, reduces dermatoneuropathic stimulation-inducing factors, increases the expression of moisturizing-related factors, increases skin absorbance, improves skin penetration, inhibits mast cell activity, and improves skin quality. Thus, it has been confirmed that the composition has excellent skin-calming and skin-irritation-relieving effects, and thus can be usefully used in skin-improving cosmetics, pharmaceuticals, and the like.

Provided herein are antibodies and antibody fragments relating to SIGLEC-8 and CD117. Provided herein are methods and compositions relating to SIGLEC-8 and / or CD117 libraries having nucleic acids encoding for a scaffold comprising a SIGLEC-8 and / or CD117 domain. SIGLEC-8 and / or CD117 libraries described herein encode for immunoglobulins such as antibodies.

Disclosed are compounds having the formula (I), or an enantiomer, diastereomer, or tautomer or atropisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein R1, R2, A and n are defined herein. Also disclosed are methods of preparing such compounds, as well as pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of inflammatory disorders, allergic disorders, skin disorders, mast cell disorders, pain disorders, and pruritus disorders. (I)

To provide methods for managing, treating, or preventing an eosinophil or mast cell related disorder and / or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).SOLUTION: The present invention provides a method including administering to a subject in need thereof a therapeutically effective amount of an antibody which specifically binds to a KIT receptor tyrosine kinase.SELECTED DRAWING: None

This invention provides a method for constructing a fluorescently traced mouse model and its application in the sorting of Mcpt4-positive and negative mast cells. First, the Cre gene is knocked into the Mcpt4 gene sequence of C57BL / 6 mice using CRISPR / Cas9 technology. Then, through animal hybridization and Cre-loxP recombination technology, a fluorescently traced mouse model of Mcpt4-positive mast cells is obtained. The fluorescently traced mouse model possesses a dual-fluorescent reporter gene system consisting of the red fluorescent protein tdTomato and the green fluorescent protein ZsGreen. Mcpt4-positive mast cells exhibit red fluorescence, while other Mcpt4-negative cells exhibit green fluorescence. Using this fluorescently traced mouse model, Mcpt4-positive and negative mast cells can be rapidly, accurately, and effectively sorted, providing a reliable technical basis for exploring the roles and mechanisms of Mcpt4-positive and negative mast cells in immune responses.

The application provides an anti-urticaria traditional Chinese medicine composition, a medicine preparation and a preparation method and application, and belongs to the field of traditional Chinese medicine compositions. The traditional Chinese medicine composition is composed of the following raw materials: 12-18 parts of Fructus Mume, 8-12 parts of Glycyrrhiza, 12-18 parts of Imperata Cylindra, 8-12 parts of Smilax Glabra, 8-12 parts of Coix Lachryma-jobi, 8-12 parts of Radix Angelicae Dahuricae, 5-7 parts of Mentha, 5-7 parts of Astragalus, 8-12 parts of Pericarpium Citri Reticulatae, and 8-12 parts of Momordica Grosvenorii. The composition follows the compatibility principle of monarch, minister, assistant and messenger, has mild medicinal properties, can significantly improve the histopathological damage of skin tissues, reduce the infiltration of mast cells, reduce the serum IgE level, correct the Th1 / Th2 immune deviation by up-regulating the Th1-type cytokine IFN-gamma and down-regulating the Th2-type cytokines IL-4, IL-5 and IL-13, and reconstruct the local immune homeostasis of skin, and has significant advantages in relieving the symptoms of urticaria and reducing the recurrence.

The invention relates to a method for depleting mast cells. The invention also relates to a method of treating mast cell disease in a subject in need thereof. The method involves administering an anti-mast cell antibody wherein the antibody is administered by a slow absorption delivery pathway, in particular wherein the antibody is administered subcutaneously. Administration of anti-mast cell antibodies via a slow absorption delivery pathway (e.g., subcutaneous or intradermal) can avoid allergic reactions occurring when anti-mast cell antibodies are administered via other pathways (e.g., intravenous).

This disclosure relates to methods of treating cancer comprising administering an effective amount of a platinum-based chemotherapy agent in combination with a microtubule associated serine / threonine-protein kinase (MAST) inhibitor and / or a glucocorticoid receptor binding agent and / or a hsp90 binding agent and / or other chemotherapy agents disclosed herein to a subject in need thereof. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising combinations of agents disclosed herein and a pharmaceutically acceptable excipient.

The invention discloses a near-infrared ratio type fluorescent probe for rapidly and reversibly detecting histamine (HA), a preparation method of the fluorescent probe and application of the fluorescent probe in dynamic cell imaging, and belongs to the technical field of fluorescence imaging and biosensing. The preparation method comprises the following specific steps: synthesizing aza-BODIPY molecules (1a-1d, 2a-2d) with different halogenations, and meanwhile, connecting the aza-BODIPY molecules with hydroxyl groups at 3 and 5 sites with a hydrophilic PEG (Polyethylene Glycol) fragment and halogen to obtain an HA probe HAPCyto with good water solubility; in addition, the hydroxyl aza-BODIPY molecules are continuously subjected to substitution, halogenation and hydrolysis reaction to obtain carboxyl-containing aza-BODIPY molecules, then the aza-BODIPY molecules are subjected to amidation reaction by utilizing the site, and different organic fragments are respectively connected to obtain a cell membrane targeted HA probe HAPPM, a golgi apparatus targeted HA probe HAPGA and a HaloTag HA fluorescent probe HAPHaloTag. When HA exists in a solution, the developed probe can realize rapid reversible detection of the near-infrared ratio of histamine, also shows good reversible property in mast cells, and can realize dynamic monitoring of histamine in cells.

The present invention relates to a composition for preventing, alleviating or treating skin wounds, comprising exosomes of mast cells. The composition according to the present invention enhances the growth and activity of fibroblasts, and thus has the effects of significantly reducing the size of wounds and shortening an initial wound treatment period.

The invention provides pediococcus acidilactici with functions of improving emotion and intestinal health and application of the pediococcus acidilactici. The pediococcus acidilactici A25-4 is preserved in Guangdong Microbial Culture Collection Center on May 23, 2025, and the preservation number of the pediococcus acidilactici A25-4 is GDMCC NO: 66384. The pediococcus acidilactici A25-4 has better cholate resistance and artificial gastrointestinal fluid resistance and can produce indole lactic acid ILA at high yield, and the optimal carbon source is fructo-oligosaccharide and galactooligosaccharide. The pediococcus acidilactici A25-4 in-vivo intervention can significantly improve the symptoms of an irritable bowel syndrome model mouse, specifically, the anxiety mood of a tested object is significantly improved; the viscera hypersensitivity of a tested object is obviously relieved; excessive activation of mast cells of a tested object is obviously inhibited; the ILA level in a tested object is obviously improved.

The present application relates to the technical field of skin care products, and discloses a composition with the effect of soothing sensitive skin, which is composed of the following components in mass percentage: plant extract 10-12%, skin repair factor 2-3%, jasmine hydrolat 10%, humectant 6-7%, and the balance being water. The composition with the effect of soothing sensitive skin has significant soothing effect, which is close to the soothing effect of common hormone ointments on the market. The composition can significantly reduce inflammatory factors, has good anti-inflammatory effect, simultaneously repairs damaged skin, enhances the moisturizing function, and enhances the skin barrier through the moisturizing and repairing effect. The composition has the effect of resisting anaphylaxis by reducing the content of trypsin and inhibiting the allergic reaction of mast cells. Human patch test and fish embryo development toxicity test prove that the composition with the effect of soothing sensitive skin has no skin adverse reactions and no development toxicity, is mild, safe and non-irritating, and is suitable for preparing skin care products for adults and infants.

The invention discloses application of transgenic zebrafish in preparation of an animal model capable of visually monitoring mast cells. The transgenic zebrafish is prepared by the following method: respectively carrying out XhoI and BamHI double enzyme digestion on a cpa5 gene promoter sequence (SEQ ID NO: 1) and plasmids with fluorescent protein genes and Tol2 transposon recognition sites, and then connecting to obtain recombinant plasmids; and then introducing the recombinant plasmid and Tol2 transposase mRNA into a zebra fish embryo in a microinjection mode in a 1-cell period of zebra fish embryo development, and culturing at constant temperature to obtain the transgenic zebra fish. The cpa5 promoter is constructed to drive an expression framework of the fluorescent protein, so that the mast cells naturally emit fluorescence in the zebra fish body, and an effective animal model is provided for mechanism research and drug screening of mast cell related diseases.

The present invention relates to a mouse SCF-neutralizing antibody and uses thereof. Specifically, the present invention relates to an antibody for neutralizing mouse SCF, comprising a heavy and a light chain of specific sequences, or an antigen-binding fragment thereof. A novel antibody is constructed for neutralizing SCF to inhibit SCF / c-kit signaling, leading to the development of a therapeutic agent for inhibiting abnormal angiogenesis, suppressing differentiation, proliferation, and degranulation of mast cells, and restraining proliferation of smooth muscle cells.

The invention belongs to the technical field of food microorganisms, and particularly relates to a lactobacillus paracasei BHP06 with an anti-allergic function. The preservation number of the Lactobacillus paracasei BHP06 is GDMCC (China General Microbiological Culture Collection Center) No: 66270, and the preservation number of the Lactobacillus paracasei BHP06 is CGMCC No: 66270. The lactobacillus paracasei strain provided by the invention has good gastrointestinal tract reverse environment resistance and has good survival ability in simulated gastrointestinal fluid; good self-aggregation capability and hyaluronidase inhibition capability are realized. By establishing a degranulation model of RBL-2H3 cells, it is found that the strain can inhibit mast cell degranulation and relieve allergy; by establishing an RAW264.7 cell inflammation model, the strain disclosed by the invention is found to be capable of inhibiting allergic inflammatory reaction; by establishing an OVA (ovalbumin)-induced BALB / c mouse food allergy model, the strain disclosed by the invention is found to be capable of improving the anti-allergy ability of animals and exerting the activity of relieving food allergy.

The invention discloses application of double-mutant zebrafish in preparation of a mast cell function defect animal model. The double-mutant zebra fish disclosed by the invention is cpa1- / -cpa5- / -double-mutant zebra fish, and is obtained by further knocking out a cpa1 gene on the basis of a cpa5- / -zebra fish mutant. According to the method, potential compensation effects of two key carboxypeptidases are eliminated at the same time, and the storage and release capacity of mast cell protease is remarkably weakened from the genetics level, so that the zebrafish animal model with the mast cell function defect, which is clear in phenotype and stable in function, is obtained. The animal model can be used for mast cell function mechanism research, related disease mechanism exploration and drug screening and evaluation, and has a good application prospect.

A method of enhancing the quality of a skin scar by topical application of an agent for improving scar quality is characterised in that said agent is pre-emptively applied to a potential surgical cutaneous site in advance of surgery, including surgery involving use of lasers. The topical agent may be a polyphenol, such as (-)-epigallocatechin-3-gallate (EGCG). Use of such a topical agent in advance of surgery leads to significant beneficial effects on dermal scarring by reducing mast cells, angiogenesis, skin thickness and simultaneously increasing elastin content. The topical agent may be applied directly or incorporated in a dressing, such as in a dermal patch comprising an adhesive silicone sheet, and can be worn both in the lead up to surgery and post-operatively.

The application relates to a compound traditional Chinese medicine composition for treating dermatitis of tumor patients, which is prepared from the following raw materials in parts by weight: 20-40 parts by weight of Huangqi, 5-15 parts by weight of Wumei, 5-15 parts by weight of Baishao, 5-15 parts by weight of Dilong and 10-20 parts by weight of Danshen, and a preparation method thereof is disclosed. The application can obviously improve the clinical dermatitis score related to skin lesions, reduce the spleen coefficient index, and also has the functions of reducing the epidermal thickness and inflammatory infiltration such as mast cells in the dermis, and reducing the inflammatory factor level in the skin lesions, which shows that the application can treat dermatitis of tumor patients.

The application discloses application of a Corydalis yanhusuo extract in preparation of an anti-allergic drug and belongs to the technical field of anti-allergic drug preparation. The treatment effect of the drug on allergic diseases is evaluated by comparing P815 cell degranulation and inflammatory factor release, the inflammatory infiltration degree of a local skin allergic reaction of a mouse, and the allergic symptoms of a mouse as a whole, so that it is determined that the Corydalis yanhusuo extract can be used for preparation of an anti-allergic drug. The Corydalis yanhusuo extract can effectively alleviate the local and systemic allergic reaction symptoms of a mouse, and reduce mast cell degranulation, and has a significant improvement effect on symptoms caused by allergic reactions.

Undesired mast cell activities are linked with various diseases or disorders, such as allergies, inflammatory diseases, autoimmune diseases, and cancers. There remains a need for new and improved therapeutics (e.g., for mast cell associated diseases or disorders) that can target c-Kit and / or siglec-6. Disclosed herein are molecules, such as antibodies and antibody fragments, capable of binding to c-Kit and / or siglec-6.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to application of a compound in preparation of an anti-allergic reaction medicine. The compound provided by the invention can effectively inhibit mast cell degranulation so as to inhibit generation of IgE-mediated I-type anaphylaxis, so that the compound is used as an anti-drug anaphylaxis preparation to provide more possible treatment schemes for clinical drug anaphylaxis treatment.

Compositions and methods for treating diseases and conditions mediated by the high affinity IgE receptor (FcεRI) are provided. Also provided are antisense oligomers for modulating splicing of mRNA encoding a MS4A6A protein, optionally in addition to antisense oligomers for modulating splicing of mRNA encoding the FcεRIβ protein, thereby down-regulating cell-surface expression of FcεRI, and uses of the antisense oligomers for inhibiting mast cell degranulation, cytokine release, migration, and proliferation; for inhibiting anaphylaxis reactions in individuals, for treating allergic conditions in individuals, for reducing the incidence of allergic reactions in individuals, for treating individuals at risk of developing anaphylactic reactions, and for treating mast cell-related diseases in individuals.

The application discloses a microfluidic chip for an allergic rhinitis model and a preparation method of an allergic rhinitis model with higher physiological correlation, higher repeatability and shorter operation period and application thereof. The application utilizes gas-liquid interface culture to induce differentiation of human primary nasal epithelial organoids, forms an epithelial model with cilia structure and barrier function, and is closer to a real physiological state. A microfluidic chip is used to simulate a local microenvironment of a human nasal cavity, the chip structure has a multi-channel separation design, integrates nasal epithelial cells, mast cells and endothelial cells, and precisely reconstructs a local allergic inflammatory response. Specific allergens can be introduced into the chip to induce allergy and excitation, a rapid and standardized allergic rhinitis in-vitro model is established, and experimental repeatability and data comparability are significantly improved.

The present disclosure relates to use of Atovaquone for treating and preventing acute and chronic inflammatory diseases in a mammal. The acute and chronic inflammatory diseases comprise mast cell-mediated inflammatory diseases.

This invention discloses an antipruritic gel containing 3-hydroxydecanoic acid microemulsion and its preparation method. The gel combines the natural antipruritic ingredient 3-hydroxydecanoic acid and peppermint oil. By preparing it into a microemulsion form, nano-sized droplets are combined with skin absorption enhancers and gel sustained-release agents, thereby improving transdermal absorption efficiency and prolonging the residence time in the skin to achieve a long-lasting antipruritic effect. 3-hydroxydecanoic acid exerts its antipruritic effect through anti-inflammatory action, blocking pruritus signaling pathways, and reducing mast cell degranulation. This antipruritic gel is stable at room temperature, easy to use, and suitable for relieving skin itching caused by mosquito bites, histamine, or non-histamine substances.

The application provides a kind of low sensitization of penaeus vannamei and its preparation method and application, belong to food biotechnology field.The application uses fucoidan to treat penaeus vannamei by covalent modification, after treatment, protein spatial conformation has changed significantly, allergen epitope is hidden.After BALB / c mouse sensitization model and RBL-2H3 cell degranulation model test shows, the sensitization of covalent modification penaeus vannamei decreases by 72.88%, low sensitization penaeus vannamei can inhibit mast cell degranulation and increase the threshold of sensitization, but still has immunogenicity.Through the construction of BALB / c mouse oral tolerance model, it is found that low sensitization penaeus vannamei can significantly alleviate the multiple immunoglobulin-mediated hypersensitivity caused by mouse allergy, which proves that low sensitization penaeus vannamei has auxiliary effect on oral tolerance, can promote oral tolerance ability, can be used as an effective immune tolerance agent for shrimp allergy patients.

The invention relates to application of bornyl acetate and an external gel preparation thereof in preparation of a medicine for relieving or treating chronic pruritus. Compared with the prior art, the bornyl acetate separated from volatile components of the folium artemisiae argyi supercritical extract has remarkable effects of inhibiting mast cell degranulation and inhibiting expression of pruritus-related factors at a cellular level and an animal level, and can be used for remarkably relieving mouse skin injury caused by DNCB; the polypeptide has the advantages of good safety, high selection index and the like, can be used for developing drugs for relieving and / or treating chronic itching and expanding treatment schemes of chronic itching, and has wide application prospects and important clinical significance.